Lena Gebert

A new megadeal in the biotech industry?💸 The German biotech CatalYm GmbH just bagged $150 million in its series D funding round. The company is developing visugromab, a monoclonal antibody targeting the growth differentiation factor-15 (GDF-15) to tackle cancer therapy resistance. ❌ The results from phase 1/2  clinical trials are extremely promising and seem to have prompted the interest of new American investors in addition to the company’s historic backers. Visugromab is the only therapy targeting the GDF-15 and this investment is set to support the candidate's development. 💊 Find out more in our article! ⬇️ https://lnkd.in/d5-CWyZJ #biotechmegadeal #cancertherapy #biotechfunding #cancerresearch #pharmainvestments #biotechinnovation #medicalresearch #biotechindustry Phil L'Huillier

139

1 Kommentar

Quantro and Boehringer Ingelheim Hit Milestone in #Cancer Treatment Development QUANTRO Therapeutics GmbH, which focuses on transcription factors targeting cancer treatments, announced that it has reached a key milestone in its joint R&D program with Boehringer Ingelheim. In successfully applying Quantro’s proprietary Quantroseq Transcriptional Fingerprint technology, all pre-set goals for technical proof-of-concept, cross-validation of HTS #screening technology, and identification of high-quality hits for a previously undruggable transcription factor were fully accomplished. Cancer, a leading global cause of death, often has limited treatment options. Transcription factors, key gene expression regulators often disrupted in cancer, are promising therapeutic targets. Despite being hard to target with drugs, the 2022 joint R&D program aims to develop innovative, first-in-class cancer treatments targeting these factors. Read more on #CMI online: https://lnkd.in/eVKrqmhv

1

For #Investors and #Media   Today Pentixapharm AG has announced the acquisition of the target discovery business of Berlin-based Glycotope GmbH. This marks a significant milestone in our journey to develop novel targeted radiopharmaceuticals for various malignancies.   🔬 This acquisition encompasses a portfolio of preclinical antibodies against multiple oncology that can be developed into #radiopharmaceuticals. It also includes laboratories and equipment, cell banks, a tumor target database, along with a range of patents, licenses and other tangible assets.   With this transaction we welcome 40 seasoned executives, R&D specialists, and administrators to our growing Pentixapharm team. This will significantly enhance our ability to develop effective diagnostics and therapeutics for patients.   You can read the full release here: https://lnkd.in/eCXh35Nw   #Pentixapharm #Glycotope #Acquisition #HealthcareInnovation #NuclearMedicine #Theranostics #Innovation #CXCR4 #ClinicalDevelopment

91

We are happy to share newsletter episode# 6 - this time about risk-based quality management. https://lnkd.in/enAyxpYN https://lnkd.in/e9KrsZYf #clinicaltrials #RBQM #GCP #KlinischePrüfungen

1

1 Kommentar

Where in Europe are innovations in drug development taking place? Drug Discovery World already asked this question in its spring print edition, highlighting the Basel Area in Switzerland as a prominent hotspot and leader in advancing European drug discovery and development, together with #Amsterdam, #Paris, and #Vilnius. Key highlights: 📍 Home to industry giants like #Roche and #Novartis, the Basel Area is a major hub for pharmaceutical innovation. Recent breakthroughs include Roche's new antibiotic targeting a high-priority pathogen. 📍 The Basel Area's thriving ecosystem supports biotech startups with strong academic partnerships and substantial investments. The region's environment fosters collaboration and innovation, attracting companies and talent worldwide. 📍 According to the Swiss Biotech Report, 20% of European biotech companies are headquartered in Switzerland, showcasing Basel’s magnetic appeal for the biotech industry. Read more about Europe's leading biotech hotspots: https://lnkd.in/e-VhPQkv ______________________________________________ Follow us on #investinbasel Basel Area Business & Innovation #Biotech #lLifeSceinces #Innovation #Research #LifeSciences #Europe #Switzerland Invest in Switzerland | Business Location Switzerland | BaseLaunch | Swiss Biotech Association | Swiss Business Hub USA | Swiss Business Hub Korea | Swiss Business Hub China | Swiss Business Hub UK

73

1 Kommentar

HTA update (G-BA Germany) >>>>Useful For HTA developer ·       Searching ICTRP for HTA could be dispensable for drug assessments, but essential for assessments of non-drug interventions. ·       >>>>IQWiG assessment shows - the ICTRP Search Portal provides about a third of the relevant study registry entries on non-drug interventions. But now we also know: Almost all relevant drug studies can be found in ClinicalTrials.gov – these saves searching the ICTRP Search Portal. Our motto when searching for evidence is: “Search completely, but efficiently! ·       In an IQWiG working paper, the search portal "International Clinical Trials Registry Platform" (IC-TRP), a WHO meta-registry, was systematically analysed for its relevance to information retrieval at IQWiG. The key question was: “Which studies of drugs and non-drug interventions included in IQWiG assessments since 2004 can only be found in the ICTRP Search Portal and not in regulatory study registries, i.e. ClinicalTrials.gov (CT.gov) of the US National Institute of Health (NIH) or the EU Clinical Trials Register (EU-CTR) of the European Medicines Agency (EMA)?” ·       More detail: https://lnkd.in/drnZZRjB #hta #gba #healthtechnology #pharmaceuticalindustry #marketaccess #costeffectiveness #systematicreview #pharma #drugpricing #pricingandreimbursement #iqwig #oncology #healtheconomics #economicmodel #costeffectiveness More detail also at: meta-data.in jagmohan.verma@vrbanalytics.com

1

𝗤𝗨𝗔𝗡𝗧𝗥𝗢 𝗧𝗵𝗲𝗿𝗮𝗽𝗲𝘂𝘁��𝗰𝘀 𝗿𝗲𝗮𝗰𝗵𝗲𝘀 𝗮 𝗺𝗶𝗹𝗲𝘀𝘁𝗼𝗻𝗲 𝗶𝗻 𝘁𝗵𝗲 𝗰𝗼𝗹𝗹𝗮𝗯𝗼𝗿𝗮𝘁𝗶𝗼𝗻 𝘄𝗶𝘁𝗵 𝗕𝗼𝗲𝗵𝗿𝗶𝗻𝗴𝗲𝗿 𝗜𝗻𝗴𝗲𝗹𝗵𝗲𝗶𝗺 𝘁𝗼 𝗱𝗲𝘃𝗲𝗹𝗼𝗽 𝗳𝗶𝗿𝘀𝘁-𝗶𝗻-𝗰𝗹𝗮𝘀𝘀 #𝗰𝗮𝗻𝗰𝗲𝗿 𝘁𝗿𝗲𝗮𝘁𝗺𝗲𝗻𝘁𝘀: QUANTRO Therapeutics GmbH, a Spin-out from the research institutes IMBA and IMP in Vienna, announced that the company has reached a key milestone in its joint R&D program with Boehringer Ingelheim. In successfully applying QUANTRO’s proprietary QUANTROseq® Transcriptional Fingerprint technology, all pre-set goals for technical proof-of-concept, cross-validation of HTS screening technology and identification of high-quality hits for a previously undruggable transcription factor were fully accomplished. For many cancer patients there are no or only limited treatment options, which is why cancer remains to be a leading cause of death worldwide, accounting for nearly one in six deaths. Transcription factors have emerged as a promising class of therapeutic targets to address currently undruggable cancers. Transcription factors are central regulators of gene expression that are commonly dysregulated in cancer and have remained largely unamenable to pharmacological intervention. The joint R&D program, which was initiated in 2022, aims at changing the implied status quo via development of transformational, first-in-class cancer treatments. 𝗥𝗲𝗮𝗱 𝗺𝗼𝗿𝗲: https://lnkd.in/ehQ6Nvsb Michael Bauer, Ph.D., Norbert Kraut

2

Julia Shanu-Wilson and Frank Scheffler are looking forward to the DMDG 5th European Biotransformation Workshop being held this Thursday 14th March at Novartis in Basel, Switzerland. There's a great line-up of topics: ·        Discussions on active metabolites and impact on drug development ·        New ways to synthesize metabolites ·        In vivo metabolite identification of oligonucleotides ·        Recommendations from recent IQ working groups on the development of targeted covalent inhibitors and best practices to conduct the Mixed Matrix Method for MIST coverage of metabolites https://lnkd.in/e6BSXfKe

20

Boehringer Ingelheim has become 𝗚𝗲𝗿𝗺𝗮𝗻𝘆'𝘀 𝗹𝗮𝗿𝗴𝗲𝘀𝘁 𝗱𝗿𝘂𝗴𝗺𝗮𝗸𝗲𝗿, surpassing Bayer | Pharmaceuticals in 2023 with 𝟮𝟬.𝟴 𝗯𝗶𝗹𝗹𝗶𝗼𝗻 𝗲𝘂𝗿𝗼𝘀 𝗶𝗻 𝗽𝗵𝗮𝗿𝗺𝗮𝗰𝗲𝘂𝘁𝗶𝗰𝗮𝗹 𝘀𝗮𝗹𝗲𝘀, driven by products like diabetes drug 𝗝𝗮𝗿𝗱𝗶𝗮𝗻𝗰𝗲 and lung drug 𝗢𝗳𝗲𝘃. This growth outpaced Bayer, whose sales 𝗱𝗿𝗼𝗽𝗽𝗲𝗱 𝟲% 𝘁𝗼 𝟭𝟴.𝟭 𝗯𝗶𝗹𝗹𝗶𝗼𝗻 𝗲𝘂𝗿𝗼𝘀. Boehringer's Jardiance sales 𝘀𝘂𝗿𝗴𝗲𝗱 𝟯𝟭% 𝘁𝗼 𝟳.𝟰 𝗯𝗶𝗹𝗹𝗶𝗼𝗻 𝗲𝘂𝗿𝗼𝘀, and they expect a slight revenue increase in 2024. They're also collaborating on a weight loss drug to compete with Eli Lilly and Company 𝗠𝗼𝘂𝗻𝗷𝗮𝗿𝗼. https://lnkd.in/e4PXe_tQ #Biotech #Pharma #Healthcare #DrugDiscovery #ClinicalTrials

6

Merck Partners with Afrigen Biologics (Pty) Ltd on #mRNA Vaccines German chemicals, #pharmaceuticals and life sciences group Merck Gruppe entered a non-binding Memorandum of Understanding (MoU) with Afrigen Biologics to support the development of an mRNA #vaccine technology platform. The collaboration is aimed at advancing mRNA platform manufacturing capabilities, scaling up production, optimizing processes, and providing troubleshooting expertise, the companies said. “Leveraging our comprehensive chemical portfolio and custom production capabilities, we offer cutting-edge experience for mRNA manufacturing, ensuring a seamless journey from research to production,” said Bert de Vet, head of Commercial EMEA Process Solutions, Life Science business sector of Merck. As part of the MoU, Merck will support Afrigen’s Center of Excellence and training initiatives aimed at building capacity in LMICs to produce mRNA vaccines and #therapeutics. The mRNA technology transfer program, co-led by the World Health Organization (WHO) and the Medicines Patent Pool (MPP), is based on a South African consortium establishing and validating an mRNA manufacturing platform at a central site and transferring the technology platform to partners. Read more on #CMI online: https://lnkd.in/exiPcAmm

2

Great news from Boston: Venture Leader Biotech Allegria Therapeutics, currently with the Swiss National Startup Team in the US, announces USD 3.5 million in seed funding raised. Applause on the deal to Maria Van Dongen and her ambitious team! https://lnkd.in/gZJJPbvM The funding was provided by Forty51 Ventures. About: Allegria Therapeutics' R&D activities focus on mast cells as mediators of allergy and inflammatory diseases, a class of indications that constitutes an increasing burden worldwide. More and more patients suffer from these conditions' impact on their quality of life. The associated socioeconomic burden is huge, and despite the growing medical need, the treatment options are still notoriously limited with overall poor outcomes. For more information and updates on Allegria Therapeutics and the Venture Leaders Biotech 2024, follow #VLeadersBioech on social media and on https://lnkd.in/dsdBqy2E. Should you be in Boston tomorrow, get your invitation to join us at Swissnex for the the Biotech Pitchfest https://lnkd.in/dfNJrfs5 and meet the full Team. This year's Venture Leaders Biotech program is co-organized by Venturelab and Swissnex in Boston and New York and supported by Debiopharm, EPFL, ETH Zürich, Hansjörg Wyss, Kellerhals Carrard Startup & VC Desk, Novartis, Swiss Biotech Association and VISCHER. #VLeadersBiotech #SwissStartups

26

1 Kommentar

✅ Discover the last session of the 10+1 Santorini Conference on May 24th at 12:20 pm! 
Get ready for an exciting panel discussion with speakers on pharmacogenomics, sponsored by PharmGenetix. 
Take the opportunity to exchange with Wolfgang Schnitzel, Mark Ruddock, Alexander Haushofer, Urs Meyer & Thomas Wilckens on this hot topic. Last chance to join us in Santorini from May 21st to 24th! ➡ https://lnkd.in/ewRNGanx #personalisedmedicine #chronicdisease #omics #pharmacology #pharmacogenomics

5

Bayer | Pharmaceuticals and Evotec link to develop precision cardiology therapeutics Bayer Pharmaceuticals division research and development head Dr Christian Rommel stated: “The refocused collaboration will leverage Evotec’s industrialised iPSC-based disease-modelling platform and Bayer’s leadership in cardiology to advance a portfolio of innovative therapies for cardiovascular diseases with high unmet medical need" Evotec chief scientific officer Dr Cord Dohrmann stated: “Our approach is based on highly validated disease models to identify novel targets and profile drug candidates more comprehensively for their efficacy and safety. Intervening with these disease-associated mechanisms more comprehensively will enable the development of more effective, disease-modifying therapies with higher relevance for CVD to respond to the substantial unmet need associated with cardiovascular diseases.” - https://lnkd.in/dzvT3Zsi #cardiology #pharma #drugdevelopment

1

𝗦𝗖𝗖𝗜𝗝 𝗡𝗲𝘄𝘀: "𝗥𝗼𝗰𝗵𝗲 𝗿𝗲𝗽𝗼𝗿𝘁𝘀 𝘀𝘂𝗰𝗰𝗲𝘀𝘀𝗲𝘀 𝘄𝗶𝘁𝗵 𝗼𝗯𝗲𝘀𝗶𝘁𝘆 𝗱𝗿𝘂𝗴𝘀" 𝘍𝘶𝘭𝘭 𝘢𝘳𝘵𝘪𝘤𝘭𝘦: https://rb.gy/rkd5uw The Swiss pharmaceutical company Roche has reported promising, albeit very early, results with two compounds it has acquired for treating #obesity and type 2 #diabetes. Big companies worldwide are searching for competitors to the bestsellers Wegovy and Ozempic which use a glucagon-like peptide-1 (GLP-1) receptor agonist.

13

For #Investors and #Media Today we are pleased to announce that Pentixapharm AG has received encouraging feedback from the FDA to directly proceed into a pivotal Phase III registration study with our radiopharmaceutical diagnostic, Ga68-PentixaFor, in Primary Aldosteronism (PA). This significant milestone paves the way for developing a first-in-class, non-invasive, and accurate alternative to adrenal venous sampling, potentially transforming diagnostic subtyping in PA and improving patient outcomes. PA is the most frequent cause of secondary hypertension (high blood pressure). 🌟 The minutes from the FDA also confirm that Ga68-PentixaFor addresses an unmet medical need for a serious condition and therefore meets two essential criteria for fast track and breakthrough designation. Read the full release here: https://lnkd.in/eEuMSHaF  #HealthcareInnovation #RadioPharmaceuticals #NuclearMedicine #Theranostics #Innovation #CXCR4

160